Thermo Fisher Scientific Inc.TMONYSE
Loading
Cash Flow Under PressureContracting
Percentile Rank64
3Y CAGR-3.1%
5Y CAGR-1.6%
Year-over-Year Change
Operating cash flow minus capital expenditures
3Y CAGR
-3.1%/yr
vs +16.2%/yr prior
5Y CAGR
-1.6%/yr
Consistent
Acceleration
-19.3pp
Decelerating
Percentile
P64
Within normal range
vs 5Y Ago
0.9x
Contraction
Streak
1 yr
Consecutive declineContracting
| Period | Value | YoY Change |
|---|---|---|
| 2025 | $6.29B | -13.4% |
| 2024 | $7.27B | +4.9% |
| 2023 | $6.93B | +0.2% |
| 2022 | $6.91B | -1.6% |
| 2021 | $7.02B | +3.0% |
| 2020 | $6.82B | +68.4% |
| 2019 | $4.05B | +6.9% |
| 2018 | $3.79B | +8.2% |
| 2017 | $3.50B | +29.0% |
| 2016 | $2.71B | - |